These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25803343)

  • 21. Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2015 Jun; 53(6):19-22. PubMed ID: 26091546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy with naltrexone and bupropion for obesity.
    Billes SK; Greenway FL
    Expert Opin Pharmacother; 2011 Aug; 12(11):1813-26. PubMed ID: 21689063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
    JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
    Barrea L; Pugliese G; Muscogiuri G; Laudisio D; Colao A; Savastano S
    Minerva Endocrinol; 2020 Jun; 45(2):127-137. PubMed ID: 32643356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.
    Wharton S; Yin P; Burrows M; Gould E; Blavignac J; Christensen RAG; Kamran E; Camacho F; Barakat M
    Int J Obes (Lond); 2021 Aug; 45(8):1687-1695. PubMed ID: 34083744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.
    Padwal R
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1117-25. PubMed ID: 19777400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Naltrexone/bupropion for obesity.
    Drug Ther Bull; 2017 Nov; 55(11):126-129. PubMed ID: 29117992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.
    Caixàs A; Albert L; Capel I; Rigla M
    Drug Des Devel Ther; 2014; 8():1419-27. PubMed ID: 25258511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug treatment of obesity: current status and future prospects.
    Kakkar AK; Dahiya N
    Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion: A Study Interrupted.
    Sharfstein JM; Psaty BM
    JAMA; 2016 Mar; 315(10):984-6. PubMed ID: 26954405
    [No Abstract]   [Full Text] [Related]  

  • 31. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.
    Grilo CM; Lydecker JA; Morgan PT; Gueorguieva R
    Clin Ther; 2021 Jan; 43(1):112-122.e1. PubMed ID: 33218742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacotherapy for obesity: What you need to know.
    Bersoux S; Byun TH; Chaliki SS; Poole KG
    Cleve Clin J Med; 2017 Dec; 84(12):951-958. PubMed ID: 29244650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview of new antiobesity drugs.
    Hainer V
    Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity.
    Kolotkin RL; Chen S; Klassen P; Gilder K; Greenway FL
    Clin Obes; 2015 Oct; 5(5):237-44. PubMed ID: 26222044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss.
    Prescrire Int; 2015 Oct; 24(164):229-33. PubMed ID: 26594724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New obesity pill: new hopes, old fears.
    Lancet; 2010 Dec; 376(9758):2042. PubMed ID: 21168038
    [No Abstract]   [Full Text] [Related]  

  • 37. What cost weight loss?
    Hiatt WR; Thomas A; Goldfine AB
    Circulation; 2012 Mar; 125(9):1171-7. PubMed ID: 22392864
    [No Abstract]   [Full Text] [Related]  

  • 38. Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.
    Citrome L
    Int J Clin Pract; 2014 Dec; 68(12):1401-5. PubMed ID: 25418525
    [No Abstract]   [Full Text] [Related]  

  • 39. Company is blamed for early halt of trial into obesity treatment.
    Wise J
    BMJ; 2016 Mar; 352():i1363. PubMed ID: 26962129
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
    Nissen SE; Wolski KE; Prcela L; Wadden T; Buse JB; Bakris G; Perez A; Smith SR
    JAMA; 2016 Mar; 315(10):990-1004. PubMed ID: 26954408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.